4.7 Article

Zika Virus Replicons for Drug Discovery

期刊

EBIOMEDICINE
卷 12, 期 -, 页码 156-160

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ebiom.2016.09.013

关键词

Zika; Drug discovery; Replicon; Flavivirus

资金

  1. Novartis Institutes for BioMedical Research
  2. University of Texas Medical Branch startup award
  3. University of Texas STARs Award
  4. NIH [R01AI087856]

向作者/读者索取更多资源

The current epidemic of Zika virus (ZIKV) has underscored the urgency to establish experimental systems for studying viral replication and pathogenesis, and countermeasure development. Here we report two ZIKV replicon systems: a luciferase replicon that can differentiate between viral translation and RNA synthesis; and a stable luciferase replicon carrying cell line that can be used to screen and characterize inhibitors of viral replication. The transient replicon was used to evaluate the effect of an NS5 polymerase mutation on viral RNA synthesis and to analyze a known ZIKV inhibitor. The replicon cell line was developed into a 96-well format for antiviral testing. Compare with virus infection-based assay, the replicon cell line allows antiviral screening without using infectious virus. Collectively, the replicon systems have provided critical tools for both basic and translational research. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据